Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.3 CHF | +0.05% | +0.72% | +19.40% |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
May. 22 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
Sales 2024 * | 10.29B 9.39B | Sales 2025 * | 10.96B 9.99B | Capitalization | 15.23B 13.89B |
---|---|---|---|---|---|
Net income 2024 * | 725M 661M | Net income 2025 * | 982M 896M | EV / Sales 2024 * | 1.78 x |
Net Debt 2024 * | 3.12B 2.84B | Net Debt 2025 * | 2.73B 2.49B | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
15.6
x | Employees | 22,633 |
Yield 2024 * |
1.77% | Yield 2025 * |
2.31% | Free-Float | 91.54% |
Latest transcript on Sandoz Group AG
1 day | -0.60% | ||
1 week | +1.29% | ||
Current month | +3.66% | ||
1 month | +7.63% | ||
3 months | +17.12% | ||
6 months | +24.05% | ||
Current year | +19.33% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 32.31 | +0.06% | 110 179 |
24-05-28 | 32.29 | -0.68% | 595,126 |
24-05-27 | 32.51 | +1.53% | 438,205 |
24-05-24 | 32.02 | -0.93% | 944,956 |
24-05-23 | 32.32 | +0.75% | 1,093,350 |
Delayed Quote Swiss Exchange, May 29, 2024 at 03:01 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.33% | 15.23B | |
+17.54% | 42.25B | |
+15.37% | 21.27B | |
+18.84% | 14.36B | |
+51.36% | 12.74B | |
-0.05% | 6.79B | |
-12.40% | 6.61B | |
-8.87% | 5.73B | |
+14.28% | 5.66B | |
+7.31% | 4.8B |
- Stock Market
- Equities
- SDZ Stock